Thromboprophylaxis Across Orthopaedic Surgery: Bibliometric Analysis of the Most Cited Articles

Overview

Journal J Clin Orthop Trauma

Specialty Orthopedics

Date 2021 Mar 15

PMID 33717952

Authors

Anil Sedani

Ramakanth Yakkanti

Paul Allegra

Lavi Mattingly

Amiethab Aiyer

Affiliations

Soon will be listed here.

Abstract

Purpose: One of the most common adverse events after orthopaedic surgery, with a potential for subsequent serious morbidity and mortality is venous thromboembolism (VTE). Bibliometric analysis has been performed regarding many topics and across orthopaedics. As DVT prophylaxis is a major component of both orthopaedic surgery considerations and research, a bibliometric analysis in this area would prove beneficial in not only in understanding the research done in the field thus far, but would also direct future research efforts.

Methods: The Web of Science (WoS) database from the Institute of Scientific Information (ISI) was used to compile articles for bibliometric analysis using Boolean search: ((Orthopaedic∗ OR Orthopaedic∗) AND (thromboprophylaxis OR Thromboembolism OR Deep vein thrombosis OR thrombus OR embolism OR anticoagulation OR Embolus OR prophylaxis)).

Results: The Top 100 cited articles included in the final list generated a total of 21,099 citations. The highest cited article was by Geerts et al. published in Chest, which had a total of 2802 on WoS, and a calculated citation density of 215.54 of citations/years since publication. Comparing the overall citation against the year of publication there was a slight positive trend favoring more recent publications (R-value: 0.142; adjusted R-squared: 0.01; p = 0.16). Analysis of an articles Level of Evidence (LOE), 17 were grade with a level of I.

Conclusions: Orthopaedic thromboprophylaxis is an ever-changing field that is at the forefront of orthopaedic literature. The significant trend favoring high quality research within orthopaedic thromboprophylaxis demonstrates the importance of this topic and there was a need for a guide to best understand the evolution of DVT prophylaxis.

References

Turpie A, Haas S, Kreutz R, Mantovani L, Pattanayak C, Holberg G . A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost. 2013; 111(1):94-102. DOI: 10.1160/TH13-08-0666. View

Eriksson B, Frison L, Eriksson U, Bylock A, Kalebo P, Fager G . A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin.... Thromb Haemost. 2002; 87(2):231-7. View

Eriksson B, Dahl O, Rosencher N, Kurth A, van Dijk C, Frostick S . Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5(11):2178-85. DOI: 10.1111/j.1538-7836.2007.02748.x. View

Hull R, Yusen R, Bergqvist D . State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost. 2009; 15(4):377-88. DOI: 10.1177/1076029609338712. View

Mueck W, Eriksson B, Bauer K, Borris L, Dahl O, Fisher W . Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008; 47(3):203-16. DOI: 10.2165/00003088-200847030-00006. View

Dahl O, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S . Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997; 77(1):26-31. View

Hohmann E, Glatt V, Tetsworth K . Orthopaedic Academic Activity in the United States: Bibliometric Analysis of Publications by City and State. J Am Acad Orthop Surg Glob Res Rev. 2018; 2(7):e027. PMC: 6145550. DOI: 10.5435/JAAOSGlobal-D-18-00027. View

Warkentin T, Cook R, Marder V, Sheppard J, Moore J, Eriksson B . Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005; 106(12):3791-6. PMC: 1895104. DOI: 10.1182/blood-2005-05-1938. View

Eriksson B, Borris L, Friedman R, Haas S, Huisman M, Kakkar A . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26):2765-75. DOI: 10.1056/NEJMoa0800374. View

10.

Colwell Jr C, Kwong L, Turpie A, Davidson B . Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty. 2006; 21(1):36-45. DOI: 10.1016/j.arth.2005.05.023. View

11.

Buller H, Deitchman D, Prins M, Segers A . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008; 6(8):1313-8. DOI: 10.1111/j.1538-7836.2008.03054.x. View

12.

Jorgensen L, Wille-Jorgensen P, Hauch O . Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg. 1993; 80(6):689-704. DOI: 10.1002/bjs.1800800607. View

13.

Anderson D, OBrien B, Levine M, Roberts R, Wells P, Hirsh J . Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med. 1993; 119(11):1105-12. DOI: 10.7326/0003-4819-119-11-199312010-00008. View

14.

Geerts W, Code K, Jay R, Chen E, Szalai J . A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994; 331(24):1601-6. DOI: 10.1056/NEJM199412153312401. View

15.

Eriksson B, Dahl O, Buller H, Hettiarachchi R, Rosencher N, Bravo M . A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005; 3(1):103-11. DOI: 10.1111/j.1538-7836.2004.01100.x. View

16.

Falck-Ytter Y, Francis C, Johanson N, Curley C, Dahl O, Schulman S . Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e278S-e325S. PMC: 3278063. DOI: 10.1378/chest.11-2404. View

17.

. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355(9212):1295-302. View

18.

Drescher F, Sirovich B, Lee A, Morrison D, Chiang W, Larson R . Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. J Hosp Med. 2014; 9(9):579-85. DOI: 10.1002/jhm.2224. View

19.

Turpie A, Bauer K, Eriksson B, Lassen M . Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest. 2004; 126(2):501-8. DOI: 10.1378/chest.126.2.501. View

20.

Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P . Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med. 1993; 153(13):1541-6. View